Physician profile
Tida Lam
NPI 1114331204
$3,102.77
in general payments reported to CMS, 2019-2025
32 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $571 · 2021: $471 · 2022: $394 · 2023: $507 · 2024: $542 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $338.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $316.77 | 2019-2024 | Breztri, Farxiga |
| Lilly USA, LLC | $294.06 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $157.99 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $127.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $125.32 | 2023-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.68 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.99 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $69.61 | 2020-2024 | Gardasil, Capvaxive, Vaxneuvance |
| Amgen INC. | $66.28 | 2019-2023 | Repatha |
| Baxter Healthcare | $62.10 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $60.83 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $56.51 | 2020-2022 | |
| Esperion Therapeutics, INC. | $50.03 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.72 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $48.12 | 2020 | |
| Phadia US INC. | $42.36 | 2019-2024 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $40.68 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.53 | 2022 | |
| Gilead Sciences, INC. | $26.78 | 2024 | |
| Exact Sciences Corporation | $19.11 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2024 | Eliquis |
| Currax Pharmaceuticals LLC | $16.99 | 2024 | Onzetra Xsail, Contrave |
| Sanofi-Aventis U.S. LLC | $16.24 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.15 | 2025 | Xhance, Nuzyra |
| Cequr Corporation | $14.97 | 2023 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.96 | 2019 | |
| Sonex Health, INC. | $13.14 | 2023 | Sx-One Microknife |
| Sanofi Pasteur INC. | $12.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tida Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.